Compulsory License Granted to Indian Pharmaceutical Company


On March 12, 2012, India’s Patent Office approved an application by Natco Pharma Limited for a compulsory license to sell a generic version of Bayer AG’s kidney and liver cancer drug Nexavar. In 2008, Bayer had filed and was granted a patent on the drug. Also, Bayer had refused to grant a voluntary license to NATCO previously.

This is the first time that an Indian company has been granted a compulsory license under the Indian Patent Act of 2005, which allows the government to require patent holders to grant licenses to third parties. The Patent Act allows any interested person, after three years from the grant of a patent, to make an application for a compulsory license on the grounds that (i) reasonable requirements of the public with respect to the patented invention have not been satisfied; (ii) the patented invention is not available to the public at a reasonable price; or (iii) the invention is not exploited commercially to the fullest extent in India. In its order, the Patent Office reasoned that Bayer had not met the reasonable requirements of the public with respect to Nexavar. It also concluded that Bayer had not exploited the drug commercially to the fullest extent in India or manufactured it to a reasonable extent in India, and that the drug was not available at an affordable price.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Miller Canfield | Attorney Advertising

Written by:


Miller Canfield on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.